United States

MicroConstants expands biomarker testing and analysis services

Wednesday, July 3, 2013 02:23 PM

MicroConstants, a CRO specializing in regulated bioanalysis and DMPK, has appointed Doinita Serban, Ph.D., director of biomarker research to oversee the expansion of biomarker testing and analysis services for preclinical and clinical diagnostic research. Doinita's experience with biomarker assay development, validation and profiling of disease panels, coupled with the implementation of the Luminex platform, will enable MicroConstants to broaden its biomarker analysis capabilities to include additional assay formats, such as multiplex immunoassays, gene expression and profiling assays.

More... »

KaloBios updates pipeline of clinical programs

Wednesday, July 3, 2013 02:19 PM

KaloBios Pharmaceuticals has updated the status of its ongoing clinical programs for KB003, KB001-A and KB004, its pipeline of proprietary monoclonal antibodies in development for severe respiratory diseases and cancer.

More... »

Morphotek announces initiation of phase I study for MORAb-066

Wednesday, July 3, 2013 02:16 PM

Biopharmaceutical Morphotek, a subsidiary of Eisai, has announced that the Sarah Cannon Research Institute in Nashville, Tenn., has opened enrollment in a phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies. The open-label, phase I study will assess the safety, tolerability and pharmacokinetics of MORAb-066 administered with weekly intravenous infusions.

More... »

Advanced Clinical Care recruiting for psoriasis trials

Wednesday, July 3, 2013 02:14 PM

Advanced Clinical Care, a Massachusetts clinical trial center, is recruiting patients for two plaque psoriasis clinical trials. Advanced Clinical Care previously has run and completed trials involving rheumatic disease. With these trials the researchers will gain knowledge about the two treatment medications for people suffering with plaque psoriasis. Both trials run for five years, providing patients free care and free medication for the entire duration of the study.

More... »

Roche Diagnostics acquires Constitution Medical

Wednesday, July 3, 2013 12:00 PM

Roche Diagnostics has acquired Boston-based Constitution Medical Investors (CMI). CMI developed a hematology testing system designed to provide faster and more accurate diagnosis of blood-related diseases, which would improve patient care. Roche will pay CMI shareholders $220 million upfront, as well as further contingent payments depending on the achievement of certain milestones. CMI will serve as a center of excellence in the field of hematology within Roche.

More... »

IP Shakti launches PipeLinX for open innovation

Wednesday, July 3, 2013 11:30 AM

IP Shakti, an early stage biomedical fund, has launched PipeLinX, a new concept in open innovation solutions. The PipeLinX service sorts through university technology to focus on emerging technologies in the field.

More... »

Royal Philips, GRMC sign 15-year alliance

Wednesday, July 3, 2013 11:00 AM

Royal Philips and Georgia Regents Medical Center (GRMC), Georgia’s public academic health center, have announced a 15-year alliance to enable patient-centered approaches to care and to create a business model that addresses current and future clinical, operational and equipment needs of GRMC sites.

More... »

Kantara Initiative, SAFE-Biopharma support NSTIC principles

Wednesday, July 3, 2013 10:41 AM

The Kantara Initiative, which helps organizations establish verified trust in use of digital identities for business and government services, and SAFE-Biopharma, which provides a global digital identity and digital signature standard for the life sciences, have pledged to adopt the four principles of the National Strategy for Trusted Identities in Cyberspace (NSTIC), the White House initiative to improve the privacy, security and convenience of sensitive online transactions.

More... »

AtheroNova initiates phase I clinical trial of AHRO-001

Wednesday, July 3, 2013 08:54 AM

AtheroNova, a biotech company focused on the R&D of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, has initiated a phase I clinical trial with its compound, AHRO-001, to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with licensing partner OOO CardioNova.

More... »

X-Change names new president

Wednesday, July 3, 2013 08:52 AM

X-Change, a company specializing in natural cannabinoid-based food and cosmetic products, has appointed former GlaxoSmithKline executive Dr. Dorothy Bray, Ph.D., president. Bray has experience in drug development, including specific expertise in plant-based research in medicine and nutrition.

More... »